Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio reported its first quarterly product revenue of $18.5 million from IBTROZI, exceeding 600 total patients treated since launch, and swung to a net income of $5.4 million driven by partnership payments. The company highlighted updated clinical data showing TKI-naïve patients achieved a median progression-free survival of 46.1 months, alongside the acquisition of Japan rights for safusidenib from Daiichi Sankyo.
Key figures
- Eps
- 0.02
- Drug Name
- IBTROZI (taletrectinib)
- Phase Of Trial
- Phase 2
- Net income
- $5.4 million
- Cash position
- $533.7 million
- C ORR TKI naive
- 89.8%
- Product revenue
- $18.5 million
- Patients on ibtrozi
- 600
- Collaboration revenue
- $64.7 million
- M DOR TKI naive months
- 49.7
- M PFS TKI naive months
- 46.1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.